Source: Υπουργείο Υγείας (CY) Revision Year: 2018 Publisher: Medochemie Ltd, 1-10 Constantinoupoleos Street, 3011 Limassol, Cyprus
Medomycin has been found clinically effective in the treatment of a variety of infections caused by susceptible strains of Gram positive and Gram negative bacteria and certain other micro-organisms.
Respiratory tract infections: Pneumonia, and other lower respiratory tract infections, due to susceptible strains of Streptococcus pneumoniae, Haemophilus influenza, Klebsiella pneumoniae, Moraxella catarrhalis and other organisms. Mycoplasma pneumoniae. Treatment of chronic bronchitis, sinusitis.
Urinary tract infections: Infections caused by susceptible strains of Klebsiella species, Enterobacter species, Escherichia coli, Streptococcus faecalis and other organisms.
Sexually transmitted diseases: Infections due to Chlamydia trachomatis, including uncomplicated urethral, endocervical or rectal infections. Non gonococcal urethritis caused by Ureaplasma urealyticum (T-mycoplasma).
Medomycin is also indicated in infections due to Calymmatobacterium granulomatis. Medomycin is an alternative drug in the treatment of gonorrhoea and syphilis.
Since Medomycin is a member of the tetracycline series of antibiotics, it may be expected to be useful in the treatment of infections which respond to other tetracyclines such as:
Ophthalmic infections: Medomycin is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral Medomycin alone or in combination with topical agents.
Rickettsial infection: Rocky Mountain spotted fever, Q fever and tick fevers and Coxiella endocarditis.
Other infections: Psittacosis, brucellosis (in combination with streptomycin), cholera, bubonic plague, louse and tick-borne relapsing fever including stage 1 and stage 2 Lyme disease, leptospirosis, tularaemia glanders, chloroquine-resistant falciparum malaria and acute intestinal amoebiasis (as an adjunct to amoebicides). Infections due to susceptible strains of Bacteroides species, Listeria species and Bacillus anthracis.
Medomycin is an alternative drug in the treatment of leptospirosis, gas gangrene and tetanus.
Medomycin is indicated for prophylaxis in the following conditions: Scrub typhus, travellers' diarrhoea (enterotoxigenic Escherichia coli), leptospirosis, malaria and cholera.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
The usual dose of Medomycin for the treatment of acute infections in adults and children aged 12 years to less than 18 years is 200 mg on the first day (administered as a single dose or divided into two equal doses with a 12 hour interval), followed by a maintenance dose of 100 mg/day.
In the management of more severe infections (particularly chronic infections of the urinary tract) 200 mg daily should be given throughout the treatment period.
Exceeding the recommended dosage may result in an increased incidence of side effects. Therapy should be continued at least 24 to 48 hours after symptoms and fever have subsided.
When used in streptococcal infections, therapy should be continued for 10 days to prevent the development of rheumatic fever or glomerulonephritis.
The use of doxycycline for the treatment of acute infections in children aged 8 years to less than 12 years should be carefully justified in situations where other drugs are not available, are not likely to be effective or are contraindicated.
In such circumstance, the doses for the treatment of acute infections are:
Doxycycline should not be used in children aged younger than 8 years due to the risk of teeth discolouration. (Section 4.4 and 4.8)
Medomycin may be prescribed in the usual dose with no special precautions. No dosage adjustment is necessary in the presence of renal impairment.
Medomycin should be administered with caution to patients with hepatic impairment or those receiving potentially hepatotoxic drugs.
Studies to date have indicated that administration of Medomycin at the usual recommended doses does not lead to accumulation of the antibiotic in patients with renal impairment.
Medomycin capsules should be taken with adequate amounts of fluid (at least 100ml of water). This should be done in the sitting or standing position and the patient should be advised to remain upright for at least thirty minutes after taking a dose. Medomycin capsules should be taken well before bedtime to reduce the risk of oesophageal irritation and ulceration. If gastric irritation occurs, it is recommended that Medomycin be given with food or milk. Studies indicate that the absorption of Medomycin is not notably influenced by simultaneous ingestion of food or milk.
Acute overdosage with antibiotics is rare. In the event of overdosage discontinue medication. Gastric lavage plus appropriate supportive treatment is indicated.
Dialysis does not alter serum half-life and thus would not be of benefit in treating cases of overdosage.
4 years.
Store 25°C in the original package, in order to protect form light and moisture.
PVC-Al blisters in cartons of 10, 20, 100 and 1000 capsules.
Not all pack sizes may be marketed.
No special requirements.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.